Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D'Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julian Panés, Laurent Peyrin-Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra SongKristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Marc Ferrante

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials'. Together they form a unique fingerprint.

Medicine & Life Sciences